Abivax SA (FR:ABVX)
:ABVX
Want to see FR:ABVX full AI Analyst Report?
Top Page
Abivax SA
(ABVX)
Select Model
Select Model
Rating:44Neutral
Price Target:
€81.00
▼(-22.64% Downside)
Action:Reiterated
Date:06/05/26
The score is held down primarily by weak financial performance (deep losses, zero/unstable revenue, and ongoing cash burn despite a stronger 2025 balance sheet) and bearish technicals (price below key moving averages with negative MACD). Valuation is only mildly supportive because negative earnings make P/E less informative and no dividend yield is available.
Positive Factors
Improved balance sheet / low leverage
The meaningful 2025 balance sheet improvement and debt at ~7% of equity materially reduces near-term refinancing pressure. This stronger capitalization provides financial flexibility to fund clinical programs and operations over the next 2-6 months without immediate forced restructuring.
Negative Factors
Persistent negative free cash flow
Sustained negative free cash flow (≈-162M in 2025) shows the company cannot self-fund operations or pivotal studies. This ongoing burn necessitates external financing, raising dilution and execution risk, and constrains long-term strategic optionality absent a visible path to cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved balance sheet / low leverage
The meaningful 2025 balance sheet improvement and debt at ~7% of equity materially reduces near-term refinancing pressure. This stronger capitalization provides financial flexibility to fund clinical programs and operations over the next 2-6 months without immediate forced restructuring.
Read all positive factors
Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€6.67B
Dividend YieldN/A
Average Volume (3M)99.97K
Price to Earnings (P/E)―
Beta (1Y)1.15
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees69
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.83
Shares Outstanding79,782,940
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€125.00Price Target Upside19.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.55
Revenue Forecast (FY)€70.21M
Abivax SA Business Overview & Revenue Model
Company Description
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ...
How the Company Makes Money
null...
Abivax SA Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -1.07M | 10.79M | 4.49M | 4.51M | -119.00K |
| EBITDA | -249.55M | -167.68M | -133.21M | -53.31M | -42.20M |
| Net Income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | |||||
| Total Assets | 584.34M | 205.23M | 327.06M | 73.35M | 110.36M |
| Cash, Cash Equivalents and Short-Term Investments | 530.38M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 32.09M | 97.36M | 55.46M | 39.16M | 53.45M |
| Total Liabilities | 129.14M | 164.64M | 131.05M | 71.47M | 81.59M |
| Stockholders Equity | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | |||||
| Free Cash Flow | -162.23M | -154.72M | -97.39M | -69.55M | -47.30M |
| Operating Cash Flow | -162.09M | -154.07M | -97.13M | -65.58M | -45.66M |
| Investing Cash Flow | -13.72M | 15.76M | -8.10M | -3.73M | -1.46M |
| Financing Cash Flow | 553.80M | 28.21M | 335.29M | 32.21M | 82.68M |
Abivax SA Technical Analysis
Negative
104.70
Price Trends
98.81
Negative
99.88
Negative
95.31
Negative
Market Momentum
-5.05
Positive
41.47
Neutral
63.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Negative. The current price of 104.7 is above the 20-day moving average (MA) of 94.70, above the 50-day MA of 98.81, and above the 200-day MA of 95.31, indicating a bearish trend. The MACD of -5.05 indicates Positive momentum. The RSI at 41.47 is Neutral, neither overbought nor oversold. The STOCH value of 63.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABVX.
Abivax SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €145.55M | -2.94 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €209.05M | -3.18 | -634.16% | ― | 291.43% | 12.24% | |
44 Neutral | €6.67B | -18.27 | ― | ― | ― | ― | |
43 Neutral | €194.56M | -4.73 | -30.75% | ― | 32.62% | -7.59% | |
42 Neutral | €874.39M | -8.56 | -241.12% | ― | ― | 27.51% | |
42 Neutral | €432.21M | -2.90 | -58.93% | ― | -15.98% | -54.34% |
* General Sector Average
FR:ABVX
Abivax SA
88.30
83.01
1569.19%
FR:IPH
Innate Pharma SA
1.58
-0.08
-5.05%
FR:DBV
DBV Technologies
2.91
1.27
76.91%
FR:TNG
Transgene
0.75
-0.18
-19.53%
FR:VLA
Valneva
2.33
-0.10
-4.24%
FR:ALCLS
Cellectis SA
2.75
1.51
121.45%
Abivax SA Corporate Events
Abivax’s obefazimod hits key phase 3 targets in ulcerative colitis
Jun 1, 2026
Abivax reported positive topline results from its global phase 3 ABTECT maintenance trial of obefazimod in adults with moderate to severe ulcerative colitis, where both 25 mg and 50 mg once-daily doses achieved significantly higher week-44 clinica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.